To report a case of Staphylococcus haemolyticus bacteremia that appeared unresponsive to vancomycin therapy alone but was successfully treated with the addition of rifampin therapy.
Setting:
Public, university, teaching hospital (University of Minnesota Hospital and Clinic, Minneapolis).
Case Summary:
A man with a history of bladder cancer developed S. haemolyticus bacteremia postoperatively that was unresponsive to vancomycin alone. The addition of oral rifampin to the vancomycin regimen provided a synergistic effect (serum inhibitory titer and serum bactericidal titer both ⩾ 1:64). The 5. haemolyticus was eradicated as judged by negative blood cultures for coagulase-negative Staphylococcus and clinical recovery.
Conclusions:
In the treatment of an S. haemolyticus bacteremia, the addition of rifampin to vancomycin therapy was effective in eliminating the organism.
Get full access to this article
View all access options for this article.
References
1.
VaraldoPEDebbiaESchitoGC. In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother1983; 23: 402–6.
2.
VeachLAPfallerMABarrettMKoontzFPWenzelRP. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol1990; 28: 2064–8.
3.
LevineDPFrommBSReddyBR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med1991; 115: 674–80.
SchwalbeRSStapletonJTGilliganPH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med1987; 316: 9027–31.
6.
National Committee for Clinical Laboratory Standards.Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. M7-T2. Villanova, PA: National Committee for Clinical Laboratory Standards, 1988.
7.
EdwinLH. Manual of clinical microbiology. 4th ed.1985, Washington, DC: American Society for Microbiology, 1985.
8.
LowyFDHammerSM. Staphylococcus epidermidis infections. Ann Intern Med1983; 99: 834–9.
9.
HunterPRGeorgeRCGriffithsJW. Mathematical modeling of antimicrobial susceptibility data of Staphylococcus haemolyticus for 11 antimicrobial agents, including three experimental glycopeptides and an experimental lipoglycopeptide. Antimicrob Agents Chemother1990; 34: 1769–72.
10.
SchwalbeRSRitzWJVermaPRBarrancoEAGilliganPH. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis1990; 161: 45–51.
11.
FroggattWJJohnsonLJGalettoDWArcherGL. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother1989; 33: 460–6.
12.
LowDEMcGeerAPoonR. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother1989; 33: 585–8.
13.
SchwarzSCardosoM. Molecular cloning, purification and properties of a plasmid-encoded chloramphenicol acetyltransferase from Staphylococcus haemolyticus. Antimicrob Agents Chemother1991; 35: 1277–83.
14.
TofteRWSollidayJRotschaferJCCrossleyKB. Staphylococcus aureus infection of dialysis shunt: Absence of synergy with vancomycin and rifampin. South Med J1981; 74: 612–5.
15.
BuggyBPScabergDRSwartzRD. Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis. Am J Med1984; 76: 1035–40.
16.
MandellGLVestTK. Killing of intra-leukocytic Staphylococcus aureus by rifampin: In-vitro and in-vivo studies. J Infect Dis1972; 125: 486–9.
17.
HolmesBQuiePGWindhorstDBPollarraBGoodRA. Protection of phagocytized bacteria from the killing action of antibiotics. Nature1966; 210: 1131–2.
18.
ArditiMYogevR. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother1989; 33: 245–7.
19.
LowlyFDChangDSLashPR. Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother1983; 23: 932–4.
20.
WatanakunakornCTisoneJC. Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother1982; 22: 920–2.
EykynSJ. Staphylococcus sepsis: The changing pattern of disease and therapy. Lancet1988; 1: 100–3.
23.
RotschaferJCGarrisonMWRodvoldKA. Therapeutic update on glycopeptide and lipopeptide antibiotics. Pharmacotherapy1988; 8: 211–9.
24.
GoldsteinFWCoutrotASiefferAAcarJF. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother1990; 34: 899–900.
